Status:
COMPLETED
Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students
Lead Sponsor:
Centre Hospitalier Universitaire de la Réunion
Conditions:
Papilloma Viral Infection
Eligibility:
All Genders
9-17 years
Phase:
PHASE4
Brief Summary
Cervical cancer (CCU) is the fourth most common cancer in women worldwide. In Reunion island, CCU is the third leading cause of cancer in women (standardized incidence rate on the world population (TI...
Eligibility Criteria
Inclusion
- schooled in one of the classes drawn at random in the 2 colleges selected for the study,
- members or beneficiaries of a social security scheme,
- having agreed to participate in the study and whose parents or holder (s) of parental authority have signed a free, informed and written consent.
Exclusion
- under the age of 9, or over the age of 17 at inclusion,
- with hypersensitivity to the active substances or to any of the excipients of the vaccine (Gardasil 9®),
- with a permanent contraindication to vaccination.
- having already initiated the HPV vaccination (complete or incomplete scheme). Students with an incomplete vaccination schedule will be referred to their attending physician to complete the missing dose (s).
- pregnancy or breastfeeding (based on the declaration)
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
355 Patients enrolled
Trial Details
Trial ID
NCT04459221
Start Date
November 1 2020
End Date
December 30 2021
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de la Réunion
Saint-Pierre, France, 97448